Mouchtouri VA, Simou E, Soteriades S, Rousou X, Kontouli KM, Kafetsouli D, Kourentis L, Anagnostopoulos L, Hadjichristodoulou C. Systematic literature review and meta-analysis on preventing and controlling norovirus outbreaks on cruise ships, 1990 to 2020: calling for behaviour change strategies of travellers. Euro Surveill. 2024 Mar 7;29(10). doi: 10.2807/1560-7917.ES.2024.29.10.2300345
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Bailey DB, Raspa M, Bishop E, Mitra D, Wheeler A, Sacco P. Health and economic consequences of Fragile X syndrome for caregivers. J Dev Behav Pediatr. 2012 Nov 1;33(9):705-12.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.